A randomised, double blind, placebo controlled, dose escalation study of aerosolized Amikacin and Fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients.

Trial Profile

A randomised, double blind, placebo controlled, dose escalation study of aerosolized Amikacin and Fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Amikacin/fosfomycin (Primary)
  • Indications Bacterial infections; Bronchitis; Pneumonia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Jun 2013 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 27 Jun 2013 Planned number of patients changed from 15 to 9 as reported by Australian New Zealand Clinical Trials Registry.
    • 22 May 2013 Interim results (n=4) presented at the 109th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top